產(chǎn)品[
CRL-1992 T2(174×CEM.T2) 人**母細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-1992 T2(174×CEM.T2) 人**母細(xì)胞
產(chǎn)品型號(hào):
CRL-1992
產(chǎn)品廠商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
CRL-1992 T2(174×CEM.T2) 人**母細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
CRL-1992 T2(174×CEM.T2) 人**母細(xì)胞
的詳細(xì)介紹
CRL-1992 T2(174×CEM.T2) 人**母細(xì)胞
|
CRL-1992™ |
|
$329.00 |
|
T2 (174 x CEM.T2) |
|
P Cresswell |
| Biosafety Level: |
2 |
|
frozen |
| Medium & Serum: |
See Propagation |
|
suspension |
|
Homo sapiens (human) |
|
lymphoblast
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| |
|
transfection host (Nucleofection technology from Lonza
Roche FuGENE® Transfection Reagents) |
|
HLA A2; CD7 + |
|
Amelogenin: X
CSF1PO: 11, 12
D13S317: 11, 12
D16S539: 10, 12
D5S818: 12, 14
D7S820: 10, 11, 15
THO1: 6, 7, 9.3
TPOX: 8, 12
vWA: 14, 17, 20 |
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Temperature: 37.0°C |
|
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) viable cells/ml and maintain between 3 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days |
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020 |
|
22647: Salter RD, et al. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246, 1985. PubMed: 3872841 |
|
